|
1
|
Matsumoto K, Nagahara T, Okano J and
Murawaki Y: The growth inhibition of hepatocellular and
cholangiocellular carcinoma cells by gemcitabine and the roles of
extracellular signal-regulated and checkpoint kinases. Oncol Rep.
20:863–872. 2008.PubMed/NCBI
|
|
2
|
Nakajima Y, Takagi H, Kakizaki S,
Horiguchi N, Sato K, Sunaga N and Mori M: Gefitinib and gemcitabine
coordinately inhibited the proliferation of cholangiocarcinoma
cells. Anticancer Res. 32:5251–5262. 2012.PubMed/NCBI
|
|
3
|
Iwaki J, Kikuchi K, Mizuguchi Y,
Kawahigashi Y, Yoshida H, Uchida E and Takizawa T: MiR-376c
down-regulation accelerates EGF-dependent migration by targeting
GRB2 in the HuCCT1 human intrahepatic cholangiocarcinoma cell line.
PLoS One. 8:e694962013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patel T: New insights into the molecular
pathogenesis of intra-hepatic cholangiocarcinoma. J Gastroenterol.
49:165–172. 2014. View Article : Google Scholar :
|
|
5
|
Jarnagin WR, Ruo L, Little SA, Klimstra D,
D'Angelica M, DeMatteo RP, Wagman R, Blumgart LH and Fong Y:
Patterns of initial disease recurrence after resection of
gallbladder carcinoma and hilar cholangiocarcinoma: Implications
for adjuvant therapeutic strategies. Cancer. 98:1689–1700. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meng F, Henson R, Lang M, Wehbe H,
Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T:
Involvement of human micro-RNA in growth and response to
chemotherapy in human cholangiocarcinoma cell lines.
Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine
versus gemcitabine for biliary tract cancer. N Engl J Med.
362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Morizane C, Okusaka T, Mizusawa J,
Takashima A, Ueno M, Ikeda M, Hamamoto Y, Ishii H, Boku N and
Furuse J: Randomized phase II study of gemcitabine plus S-1 versus
S-1 in advanced biliary tract cancer: A Japan Clinical Oncology
Group trial (JCOG 0805). Cancer Sci. 104:1211–1216. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miyoshi H, Kato K, Iwama H, Maeda E,
Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, et al:
Effect of the anti-diabetic drug metformin in hepatocellular
carcinoma in vitro and in vivo. Int J Oncol. 45:322–332.
2014.PubMed/NCBI
|
|
10
|
Haga H, Yan I, Takahashi K, Wood J and
Patel T: Emerging insights into the role of microRNAs in the
pathogenesis of cholangiocarcinoma. Gene Expr. 16:93–99. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The anti-diabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kobayashi M, Kato K, Iwama H, Fujihara S,
Nishiyama N, Mimura S, Toyota Y, Nomura T, Nomura K, Tani J, et al:
Antitumor effect of metformin in esophageal cancer: In vitro study.
Int J Oncol. 42:517–524. 2013.
|
|
13
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: Procedure and some applications. Proc Natl
Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Masaki T, Okada M, Shiratori Y, Rengifo W,
Matsumoto K, Maeda S, Kato N, Kanai F, Komatsu Y, Nishioka M, et
al: pp60c-src activation in hepatocellular carcinoma of humans and
LEC rats. Hepatology. 27:1257–1264. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Masaki T, Shiratori Y, Rengifo W, Igarashi
K, Matsumoto K, Nishioka M, Hatanaka Y and Omata M: Hepatocellular
carcinoma cell cycle: Study of Long-Evans cinnamon rats.
Hepatology. 32:711–720. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morishita A, Masaki T, Yoshiji H, Nakai S,
Ogi T, Miyauchi Y, Yoshida S, Funaki T, Uchida N, Kita Y, et al:
Reduced expression of cell cycle regulator p18(INK4C) in human
hepatocellular carcinoma. Hepatology. 40:677–686. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Katsura A, Morishita A, Iwama H, Tani J,
Sakamoto T, Tatsuta M, Toyota Y, Fujita K, Kato K, Maeda E, et al:
MicroRNA profiles following metformin treatment in a mouse model of
non-alcoholic steatohepatitis. Int J Mol Med. 35:877–884.
2015.PubMed/NCBI
|
|
20
|
Anderson CD, Pinson CW, Berlin J and Chari
RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist.
9:43–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Zhou Y, Zhou H, Jia G, Liu J, Han
B, Cheng Z, Jiang H, Pan S and Sun B: Pristimerin causes G1 arrest,
induces apoptosis, and enhances the chemosensitivity to gemcitabine
in pancreatic cancer cells. PLoS One. 7:e438262012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hong DS, Angelo LS and Kurzrock R:
Interleukin-6 and its receptor in cancer: Implications for
translational therapeutics. Cancer. 110:1911–1928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Waugh DJJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Okabe H, Beppu T, Ueda M, Hayashi H,
Ishiko T, Masuda T, Otao R, Horlad H, Mima K, Miyake K, et al:
Identification of CXCL5/ENA-78 as a factor involved in the
interaction between cholangiocarcinoma cells and cancer-associated
fibroblasts. Int J Cancer. 131:2234–2241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Salcedo R, Ponce ML, Young HA, Wasserman
K, Ward JM, Kleinman HK, Oppenheim JJ and Murphy WJ: Human
endothelial cells express CCR2 and respond to MCP-1: Direct role of
MCP-1 in angiogenesis and tumor progression. Blood. 96:34–40.
2000.PubMed/NCBI
|
|
26
|
Takamizawa J, Konishi H, Yanagisawa K,
Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y,
et al: Reduced expression of the let-7 microRNAs in human lung
cancers in association with shortened postoperative survival.
Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong
C, Huang Y, Hu X, Su F, Lieberman J, et al: let-7 regulates self
renewal and tumorigenicity of breast cancer cells. Cell.
131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Akao Y, Nakagawa Y and Naoe T: let-7
microRNA functions as a potential growth suppressor in human colon
cancer cells. Biol Pharm Bull. 29:903–906. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu X-M, Wu L-J, Xu J, Yang R and Wu F-S:
Let-7c microRNA expression and clinical significance in
hepatocellular carcinoma. J Int Med Res. 39:2323–2329. 2011.
View Article : Google Scholar
|
|
30
|
Johnson SM, Grosshans H, Shingara J, Byrom
M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D and Slack
FJ: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee YS and Dutta A: The tumor suppressor
microRNA let-7 represses the HMGA2 oncogene. Genes Dev.
21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Osada H and Takahashi T: let-7 and
miR-17-92: Small-sized major players in lung cancer development.
Cancer Sci. 102:9–17. 2011. View Article : Google Scholar
|
|
33
|
Liu Y, Yin B, Zhang C, Zhou L and Fan J:
Hsa-let-7a functions as a tumor suppressor in renal cell carcinoma
cell lines by targeting c-myc. Biochem Biophys Res Commun.
417:371–375. 2012. View Article : Google Scholar
|
|
34
|
Wang X, Chen J, Li F, Lin Y, Zhang X, Lv Z
and Jiang J: MiR-214 inhibits cell growth in hepatocellular
carcinoma through suppression of β-catenin. Biochem Biophys Res
Commun. 428:525–531. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiao Z, Li CH, Chan SL, Xu F, Feng L, Wang
Y, Jiang JD, Sung JJ, Cheng CH and Chen Y: A small-molecule
modulator of the tumor-suppressor miR34a inhibits the growth of
hepato-cellular carcinoma. Cancer Res. 74:6236–6247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guo Y, Li S, Qu J, Wang S, Dang Y, Fan J,
Yu S and Zhang J: MiR-34a inhibits lymphatic metastasis potential
of mouse hepatoma cells. Mol Cell Biochem. 354:275–282. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hirata H, Ueno K, Nakajima K, Tabatabai
ZL, Hinoda Y, Ishi N and Dahiya R: Genistein downregulates
onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells.
Br J Cancer. 108:2070–2078. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sand M, Skrygan M, Sand D, Georgas D,
Gambichler T, Hahn SA, Altmeyer P and Bechara FG: Comparative
microarray analysis of microRNA expression profiles in primary
cutaneous malignant melanoma, cutaneous malignant melanoma
metastases, and benign melanocytic nevi. Cell Tissue Res.
351:85–98. 2013. View Article : Google Scholar
|
|
39
|
Yang Y-F, Wang F, Xiao J-J, Song Y, Zhao
YY, Cao Y, Bei YH and Yang CQ: MiR-222 overexpression promotes
proliferation of human hepatocellular carcinoma HepG2 cells by
downregulating p27. Int J Clin Exp Med. 7:893–902. 2014.PubMed/NCBI
|
|
40
|
Sun C, Li N, Zhou B, Yang Z, Ding D, Weng
D, Meng L, Wang S, Zhou J, Ma D, et al: miR-222 is upregulated in
epithelial ovarian cancer and promotes cell proliferation by
downregulating P27(kip1). Oncol Lett. 6:507–512. 2013.PubMed/NCBI
|
|
41
|
Saito Y, Suzuki H, Matsuura M, Sato A,
Kasai Y, Yamada K, Saito H and Hibi T: MicroRNAs in hepatobiliary
and pancreatic cancers. Front Genet. 2:662011. View Article : Google Scholar
|
|
42
|
Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F,
Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z and Chun-Sheng
K: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell
proliferation and radioresistance by targeting PTEN. BMC Cancer.
10:3672010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Visone R, Russo L, Pallante P, De Martino
I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM, et
al: MicroRNAs (miR)-221 and miR-222, both overexpressed in human
thyroid papillary carcinomas, regulate p27Kip1 protein levels and
cell cycle. Endocr Relat Cancer. 14:791–798. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Võsa U, Vooder T, Kolde R, Vilo J,
Metspalu A and Annilo T: Meta-analysis of microRNA expression in
lung cancer. Int J Cancer. 132:2884–2893. 2013. View Article : Google Scholar
|
|
45
|
Sugimachi K, Aishima S, Taguchi K, Tanaka
S, Shimada M, Kajiyama K, Sugimachi K and Tsuneyoshi M: The role of
over-expression and gene amplification of cyclin D1 in intrahepatic
cholangiocarcinoma. J Hepatol. 35:74–79. 2001. View Article : Google Scholar : PubMed/NCBI
|
